Wolff Wiese Magana LLC Has $1.53 Million Holdings in Merck & Co., Inc. $MRK

Wolff Wiese Magana LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 0.9% during the second quarter, HoldingsChannel.com reports. The firm owned 19,316 shares of the company’s stock after acquiring an additional 174 shares during the quarter. Wolff Wiese Magana LLC’s holdings in Merck & Co., Inc. were worth $1,529,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in MRK. Legend Financial Advisors Inc. acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $25,000. Barnes Dennig Private Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $27,000. CBIZ Investment Advisory Services LLC boosted its position in shares of Merck & Co., Inc. by 141.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after acquiring an additional 221 shares in the last quarter. MorganRosel Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $36,000. Finally, MJT & Associates Financial Advisory Group Inc. acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $48,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Wells Fargo & Company reduced their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Finally, Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price target for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $106.41.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $78.51 on Monday. The company has a market cap of $196.10 billion, a price-to-earnings ratio of 12.10, a PEG ratio of 0.81 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The firm has a 50 day simple moving average of $82.53 and a 200 day simple moving average of $81.81. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $114.79.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, beating the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 7th. Investors of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 4.1%. Merck & Co., Inc.’s payout ratio is currently 49.92%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.